Chronic stable angina positron emission tomography (PET)

Chronic stable angina Microchapters
Acute Coronary Syndrome Main Page
Home
Patient Information
Overview
Historical Perspective
Classification
Classic Chronic Stable Angina
Atypical Walk through Angina Mixed Angina Nocturnal Angina Postprandial Angina Cardiac Syndrome X Vasospastic Angina
Differentiating Chronic Stable Angina from Acute Coronary Syndromes
Pathophysiology
Epidemiology and Demographics
Risk Stratification
Pretest Probability of CAD in a Patient with Angina
Prognosis
Diagnosis
History and Symptoms
Physical Examination
Test Selection Guideline for the Individual Basis
Laboratory Findings
Electrocardiogram
Exercise ECG
Chest X Ray
Myocardial Perfusion Scintigraphy with Pharmacologic Stress
Myocardial Perfusion Scintigraphy with Thallium
Echocardiography
Exercise Echocardiography
Computed coronary tomography angiography(CCTA)
Positron Emission Tomography
Ambulatory ST Segment Monitoring
Electron Beam Tomography
Cardiac Magnetic Resonance Imaging
Coronary Angiography
Treatment
Medical Therapy
Revascularization
PCI
CABG
Hybrid Coronary Revascularization
Alternative Therapies for Refractory Angina
Transmyocardial Revascularization (TMR)
Spinal Cord Stimulation (SCS)
Enhanced External Counter Pulsation (EECP)
ACC/AHA Guidelines for Alternative Therapies in patients with Refractory Angina
Discharge Care
Patient Follow-Up
Rehabilitation
Secondary Prevention
Guidelines for Asymptomatic Patients
Noninvasive Testing in Asymptomatic Patients
Risk Stratification by Coronary Angiography
Pharmacotherapy to Prevent MI and Death in Asymptomatic Patients
Landmark Trials
Case Studies
Case #1
Chronic stable angina positron emission tomography (PET) On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Chronic stable angina positron emission tomography (PET)
CDC onChronic stable angina positron emission tomography (PET)
Chronic stable angina positron emission tomography (PET) in the news
Blogs on Chronic stable angina positron emission tomography (PET)
to Hospitals Treating Chronic stable angina positron emission tomography (PET)
Risk calculators and risk factors for Chronic stable angina positron emission tomography (PET)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Smita Kohli, M.D.

Overview

Positron emission tomography is of particular value in the assessment of regional coronary blood flow reserve, myocardial perfusion, and the presence and extent of hibernating myocardium.

PET

• Rubidium-82 or ammonia (N13) can be used for assessment of myocardial perfusion.
• Labeled carbohydrates such as fludeoxyglucose F-18, lipids, and some amino acids can be used to asses myocardial metabolism and viable ischemic myocardium.

Indications

PET is of value principally in difficult situations where in myocardial perfusion by thallium scintigraphy and assessment of left ventricular systolic function by echocardiography do not reveal the extent of hibernating myocardium.

Sensitivity and Specificity

With combined assessment of myocardial perfusion and metabolism, the sensitivity and specificity for the detection of CAD may approach 95%.

Disadvantages

Positron emission tomography is a very expensive noninvasive test and not readily available in every cardiac diagnostic care center.

For more information on techniques used to assess myocardial viability, click here.

References

Template:WikiDoc Sources